TRIL News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

TR

Volume

538

Loading chart

TR

TRILVegaShares Trillions ETF

TRIL

Pay with—

Available Balance0.00

TR

AUM

N/A

Volume

538

Yield

N/A

Chart Earnings News About Insider Filings

Trillium Therapeutics Receives Final Court Order Approving ArrangementCAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is pleased to announce that it has received a final order from the Supreme Court of British Columbia approving the previously announced plan of arrangement (the “Arrangement”) with PF Argentum ULC (“PF Argentum”), a wholly-owned, indirect subsidiary of Pfizer Inc. (NYSE: PFE) (“Pfizer”).GlobeNewswire Inc. · Oct 28, 2021

3 Pharma Stocks You Can Buy and Hold ForeverThese drugmakers are built to last.The Motley Fool · Oct 28, 2021

2 Top Dividend Stocks That Can Safeguard Your Portfolio Against a Market CrashThese two pharma giants are among the safest plays in the market right now.The Motley Fool · Oct 27, 2021

Trillium Securityholders Approve Acquisition by PfizerCAMBRIDGE, Mass., Oct. 26, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, today announced that its securityholders approved a statutory arrangement with PF Argentum ULC (“PF Argentum”) a wholly-owned, indirect subsidiary of Pfizer Inc. (NYSE: PFE) (“Pfizer”) at the special meeting of Trillium securityholders today. Pursuant to the arrangement, PF Argentum will acquire all of the issued and outstanding shares and warrants of Trillium, other than Trillium securities owned by Pfizer and its affiliates.GlobeNewswire Inc. · Oct 26, 2021

2 Top Healthcare Stocks That Could Be Bought Out in 2022These two novel-drug makers could be top takeover targets next year.The Motley Fool · Oct 16, 2021

Better COVID-19 Stock: Merck or Pfizer?Here's how the two big-pharma stocks stack up against each other.The Motley Fool · Oct 16, 2021

3 Safe Dividend Stocks to Buy Right NowThey'll pay you much more than the paltry return you'll get with the average stock in the S&P 500.The Motley Fool · Oct 5, 2021

Thinking of Buying Pfizer Stock? Here's What You Need to KnowPfizer sells the leading COVID-19 vaccine -- and seven other blockbusters.The Motley Fool · Sep 27, 2021

Moderna's COVID Vaccine Could Be Better Than Pfizer's -- Here's Why Its Stock Isn'tThere are a couple of big reasons why Moderna stock isn't as good of a pick as Pfizer right now.The Motley Fool · Sep 22, 2021

Is Pfizer Stock a Buy After an FDA Panel Recommended Boosters for Ages 65 and Up?Yes -- and no.The Motley Fool · Sep 21, 2021

to start trading

TR

TRILVegaShares Trillions ETF

TRIL

Pay with—

Available Balance0.00

Your PositionYou don't own any TRIL yet.

Related Tickers

Earnings